highlight
one
import
accomplish
recent
drug
discoveri
antivir
research
identif
hepat
c
viru
directact
antivir
sofosbuvir
new
altern
combat
hepat
b
viru
hbv
infect
lectur
award
david
chu
medicin
chemistri
provid
overview
earli
develop
nucleosid
analog
treatment
hiv
varicella
zoster
viru
infect
knowledg
serv
develop
new
drug
target
hbv
priscilla
yang
gave
first
isar
women
scienc
lectur
report
pharmacolog
valid
new
antivir
target
dengu
zika
flavivirus
william
prusoff
young
investig
lectur
award
maaik
evert
describ
alabama
drug
discoveri
allianc
antivir
drug
discoveri
develop
consortium
help
acceler
develop
new
antivir
icar
success
promot
new
discoveri
antivir
drug
develop
research
icar
held
porto
portug
june
intern
societi
antivir
research
isar
sponsor
annual
intern
meet
intern
confer
antivir
research
icar
icar
held
atlanta
georgia
usa
may
previou
year
vere
hodg
hodg
hodg
meet
provid
interdisciplinari
forum
investig
involv
basic
translat
clinic
research
worldwid
met
review
recent
develop
area
antivir
research
drug
vaccin
develop
critic
success
discoveri
develop
new
therapi
requir
close
cooper
among
scientist
divers
scientif
disciplin
overarch
goal
confer
drive
discoveri
new
antivir
therapi
foster
collabor
among
scientist
field
basic
virolog
medicin
chemistri
pharmacolog
anim
model
diseas
toxicolog
academia
pharmaceut
industri
year
icar
present
two
symposia
highlight
potenti
opportun
research
establish
collabor
work
group
antivir
immun
symposium
discuss
strategi
util
immun
respons
host
conjunct
antivir
drug
control
chronic
infect
hepat
b
viru
hbv
human
immunodefici
viru
hiv
infect
new
small
molecul
target
viral
entri
flaviviru
influenza
viru
infect
also
discuss
emerg
infect
symposium
discuss
viral
infect
global
concern
potenti
antivir
drug
treat
infect
mitig
effect
emerg
epidem
includ
hemorrhag
fever
virus
rodentborn
virus
emerg
coronaviru
pandem
diseas
respiratori
viru
session
describ
common
respiratori
viral
diseas
respiratori
syncyti
viru
human
coronavirus
enterovirus
caus
signific
morbid
mortal
session
includ
hepat
virus
retrovirus
emerg
virus
dna
respiratori
virus
medicin
chemistri
complet
icar
program
avail
http
cymcdncomsiteswwwisaricarcomresourceresmgrdoc
report
eight
volunt
rapporteur
provid
summari
princip
scientif
present
icar
hope
effect
convey
speaker
goal
result
conclus
talk
articl
cover
session
oral
poster
present
event
taken
comprehens
account
meet
howev
provid
overview
award
lectur
invit
keynot
talk
present
perspect
expert
antivir
research
gertrud
elion
memori
lectur
award
michael
j
sofia
arbutu
biopharma
doylestown
pa
michael
mike
sofia
began
lectur
note
expert
consid
hepat
b
c
pose
similar
challeng
antivir
therapi
predict
effect
cure
hepat
c
would
develop
earlier
expect
achiev
goal
fig
attribut
part
recognit
pharmasset
scientist
year
ago
compound
cmethylcytidin
sever
promis
featur
activ
antivir
research
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
n
v
r
l
polymeras
hcv
genotyp
high
barrier
resist
good
safeti
profil
show
addit
synergist
activ
vitro
combin
ribavirin
interferon
clark
et
al
pharmasset
team
work
overcom
limit
includ
rel
low
uptak
gastrointestin
tract
slow
initi
phosphoryl
within
cell
product
inact
uridin
metabolit
improv
uptak
evalu
prodrug
includ
molecul
prove
well
toler
perform
well
combin
ribavirin
pegifn
le
pogam
et
al
show
addit
potenc
combin
novel
proteas
inhibitor
gane
et
al
although
continu
advanc
toward
clinic
use
requir
larg
dose
efficaci
clear
someth
better
would
need
point
mike
team
decid
exploit
inher
enzymat
activ
hepatocyt
creat
monophosph
prodrug
would
undergo
seri
cleavag
unmask
phosphat
group
new
compound
prove
activ
patient
limit
presenc
activ
inact
stereoisom
final
success
achiev
novel
synthet
method
produc
molecul
known
sofosbuvir
ross
et
al
true
watersh
moment
came
electron
studi
genotyp
patient
cours
sofosbuvir
plu
ribavirin
produc
cure
rate
rest
histori
mike
turn
attent
chronic
hepat
b
current
manag
longterm
administr
nucleosidetid
analog
pegifn
suppress
viral
replic
slow
diseas
progress
rare
produc
cure
two
factor
respons
limit
efficaci
current
treatment
state
immun
toler
induc
massiv
continu
product
subvir
particl
persist
cccdna
hbv
genom
nucleu
infect
cell
doubl
barrier
discourag
research
effort
except
new
alafenamid
prodrug
tenofovir
new
antihbv
drug
introduc
past
year
fig
remaind
lectur
describ
unpublish
research
team
arbutu
recogn
cur
therapi
hepat
b
must
inhibit
viral
replic
restor
immun
function
like
requir
combin
drug
differ
mechan
action
take
two
differ
approach
first
focus
inhibit
assembl
viral
capsid
requir
encapsid
pregnom
rna
subsequ
synthesi
cccdna
lead
arbutu
compound
appear
act
bind
site
interfac
capsid
dimer
highli
conserv
among
viral
genotyp
test
hbvinfect
mice
fulli
human
liver
show
significantli
lower
viral
dna
level
addit
effect
entecavir
second
approach
aim
block
aspect
hbv
replic
simultan
deliveri
hepatocyt
three
differ
rnai
trigger
target
four
viral
rna
transcript
arbutu
research
hope
abruptli
halt
antigen
product
approach
reawaken
immun
system
lead
product
target
conserv
rna
sequenc
expect
effect
viral
genotyp
regardless
treatment
statu
combin
therapi
secondgener
rnai
product
shown
greater
potenc
prolong
activ
mice
expect
tripl
combin
therapi
entecavir
pegifn
highli
effect
produc
greatest
delay
viral
recoveri
greatest
suppress
serum
hbsag
suppress
hbsag
product
correl
gain
ifna
express
augur
recoveri
host
immun
respons
yet
test
human
phase
ii
studi
patient
chronic
nucleosid
analog
therapi
found
addit
decreas
circul
hbsag
hbeagposit
neg
patient
novel
approach
offer
prospect
effect
suppress
hbv
replic
produc
cure
answer
year
away
first
part
lectur
david
chu
review
synthesi
antihiv
activ
diaminopurin
dioxolan
dapdamdoxovir
dioxolan
thymin
dot
fig
two
class
nucleosid
analog
potent
vitro
vivo
activ
chemic
synthesi
vitro
evalu
dioxolan
nucleosid
potenti
antihiv
agent
dapd
dioxolanediaminopurin
discov
interest
antihiv
agent
inhibit
drugresist
hiv
mutant
azt
lamivudin
nonnucleosid
revers
transcriptas
inhibitor
nnrti
vitro
chen
et
al
furman
et
al
underw
phase
iia
clinic
trial
demonstr
efficaci
patient
drugresist
hiv
dapd
purin
analog
fig
biochem
prodrug
guanin
analog
dxg
convert
guanin
analog
adenosin
deaminas
vitro
vivo
dapd
solubl
water
guanin
analog
dxg
provid
better
physicochem
properti
drug
order
understand
molecular
mechan
dapd
dxg
triphosph
triphosph
still
effect
drugresist
hiv
molecular
model
studi
conduct
found
oxygen
atom
dioxolanemoieti
promot
bind
dapd
hivrt
anoth
dioxolan
nucleosid
discov
interest
antihiv
agent
dot
dioxolanethymin
fig
dot
effect
drugresist
hiv
mutant
etc
david
review
histori
potenti
new
therapi
varicella
zoster
viru
vzv
caus
chickenpox
children
zoster
shingl
older
adult
usa
europ
approv
drug
includ
acyclovir
deriv
foscarnet
brivudin
bvdu
fig
licens
european
countri
usa
compound
block
enzymat
degrad
cancer
drug
caus
sever
toxic
death
patient
receiv
medic
effort
identifi
altern
bvdu
dnucleosid
would
block
catabol
david
colleagu
synthes
test
seri
lanalog
bvdu
vzv
infect
primari
human
foreskin
fibroblast
skin
organ
cultur
choi
et
al
de
et
al
identifi
hydroxymethyl
uracil
lbhdu
especi
promis
compound
minim
cytotox
effect
concentr
ec
valu
vzv
significantli
lower
acyclovir
foscarnet
lbhdu
evalu
jennif
moffat
colleagu
model
vzv
infect
human
skin
xenograft
scid
mice
found
potent
acyclovir
valacyclovir
importantli
hplc
analysi
show
bvdu
prevent
breakdown
lbhdu
interfer
catabol
suggest
drug
would
safe
cancer
patient
therapi
first
time
lnucleosid
shown
effect
herp
viru
therapi
continu
review
lnucleosid
antivir
agent
david
shift
topic
hepat
b
first
discuss
histori
clevudin
lfmau
levovir
shown
year
ago
good
activ
hbv
potent
danalog
et
al
work
tennant
korba
colleagu
clevudin
found
highli
effect
woodchuck
hepat
model
rapidli
induc
profound
suppress
viremia
persist
week
cessat
therapi
peek
et
al
also
highli
effect
phase
iiiii
clinic
studi
induc
drop
viremia
e
patient
clevudin
use
south
korea
sever
countri
phase
iii
develop
usa
pharmasset
discontinu
david
conclud
lectur
review
develop
hbv
inhibitor
novel
carbocycl
adenosin
analog
hbv
hydroxymethyl
methylenecarbocycl
adenosin
fmca
fig
particularli
use
activ
virus
resist
lamivudin
entecavir
rawal
et
al
synthes
phosphoramid
prodrug
fmcap
show
good
efficaci
hydrodynam
mous
model
hepat
b
vivo
evalu
ongo
women
scienc
award
present
priscilla
yang
harvard
medic
school
boston
priscilla
yang
research
group
focus
pharmacolog
valid
new
antivir
target
dengu
denv
zika
zikv
flavivirus
princip
target
effort
block
viral
fusion
entri
tradit
base
antibodi
envelop
e
glycoprotein
reason
e
could
also
target
small
molecul
fusion
process
catalyt
low
endosom
ph
trigger
structur
chang
e
lower
energi
barrier
membran
fusion
howev
contrast
smallmolecul
target
e
nt
classic
activ
site
coval
bond
made
broken
also
clear
candid
drug
might
bind
possibl
ligandbind
pocket
observ
initi
effort
determin
structur
e
protein
cocrystal
presenc
deterg
betaoctoglucosid
unclear
whether
pocket
bonafid
antivir
target
modi
et
al
modi
et
al
answer
question
priscilla
group
began
use
cellbas
phenotyp
screen
denvinfect
cell
identifi
activ
compound
detect
e
express
immunofluoresc
autom
microscopi
follow
timeofaddit
experi
discrimin
inhibitor
viru
entri
block
later
step
replic
chu
yang
clark
et
al
screen
identifi
three
seri
small
molecul
pyrimidin
cyanohydrazonesthat
interfer
entri
link
compound
biotin
fluorophor
group
shown
inhibitor
interact
solubl
prefus
e
dimer
postfus
trimer
clark
et
al
fig
block
phtrigger
emedi
fusion
virion
liposom
unpublish
howev
yet
succeed
obtain
highresolut
structur
compound
bound
recombin
prefus
e
identifi
bind
site
priscilla
team
perform
serial
viru
passag
presenc
compound
found
resist
mutat
locat
base
ligandbind
pocket
e
domain
ii
attempt
engin
resist
introduc
mutat
unsuccess
suggest
modifi
bind
site
fit
cost
examin
sequenc
divers
analog
pocket
present
multipl
denv
isol
team
engin
six
differ
substitut
recombin
e
protein
measur
kd
valu
repres
compound
three
inhibitor
seri
compound
affect
least
mutat
pocket
differ
footprint
howev
footprint
inhibitor
class
similar
two
class
comparison
aminoacid
sequenc
among
differ
flaviviru
speci
reveal
residu
deep
pocket
broadli
conserv
test
zika
west
nile
japanes
enceph
virus
cyanohydrazon
compound
broadspectrum
activ
two
pyrimidin
seri
activ
denv
effort
better
understand
chemic
divers
engag
detergentbind
pocket
priscilla
group
develop
alphascreen
assay
base
detect
displac
biotinyl
pyrimidin
inhibitor
bound
target
site
screen
compound
produc
lead
inhibitori
concentr
ic
valu
correl
well
effect
concentr
ec
valu
cell
cultur
kd
recombin
e
indic
alphascreen
good
tool
find
compound
bind
pocket
inhibit
fusion
collabor
steve
harrison
luke
chao
use
fluorophoreconjug
inhibitor
singleparticl
fusion
assay
examin
stoichiometri
inhibitor
bind
found
approxim
molecul
cyanohydrazon
must
bind
vlp
inhibit
fusion
vlp
copi
e
schmidt
et
al
current
effort
aim
determin
greater
number
pyrimidin
molecul
must
bind
viral
particl
block
fusion
number
correl
breadth
activ
differ
flavivirus
also
work
develop
addit
inhibitor
valid
antivir
strategi
vivo
maaik
evert
first
describ
alabama
drug
discoveri
allianc
adda
creat
rich
whitley
uab
jack
secrist
southern
research
sr
recogn
institut
possess
complementari
scientif
manag
expertis
work
togeth
could
cover
step
discov
new
drug
move
forward
clinic
evert
et
al
also
realiz
earli
phase
drug
discoveri
assay
develop
highthroughput
screen
ht
could
best
fund
institut
invest
later
phase
requir
signific
medicin
chemistri
effort
support
state
philanthrop
dollar
key
ingredi
success
adda
regular
meet
pi
sit
interdisciplinari
team
discuss
progress
solv
problem
importantli
licens
associ
technolog
transfer
offic
particip
process
begin
long
patent
applic
file
adda
project
pipelin
rang
earli
assay
develop
phase
clinic
trial
base
success
adda
uabsr
team
obtain
grant
nih
establish
antivir
drug
discoveri
develop
consortium
fig
combin
expertis
promin
virologist
academ
center
pharmaceut
industri
ht
medicin
chemistri
resourc
sr
evert
et
al
evert
et
al
current
focus
countermeasur
develop
import
pathogen
flaviviru
alphaviru
coronaviru
famili
influenza
virus
key
factor
success
factor
includ
foundat
experi
basic
virolog
drug
discoveri
develop
regular
commun
phone
facetofac
meet
excel
advisori
board
help
strateg
decis
anoth
major
factor
sens
cohes
provid
richard
rich
whitley
vast
experi
virolog
drug
develop
serv
nucleu
consortium
websit
adda
http
wwwuabedumedicineadda
http
wwwuabedu
year
session
brought
togeth
individu
expertis
experi
relev
creat
biotechnolog
compani
robert
bob
buckheit
imquest
bioscienc
frederick
md
mike
sofia
present
experi
start
lead
success
compani
perspect
contract
research
therapeut
discoveri
develop
respect
bob
start
introduct
biotechnolog
industri
begin
genetech
highlight
motiv
start
enterpris
driven
desir
someth
good
societi
translat
academ
discoveri
market
product
stress
need
solid
busi
plan
honest
assess
inher
risk
emphas
necess
address
unmet
need
assembl
high
qualiti
team
speak
challeng
start
compani
focus
discoveri
develop
therapeut
mike
highlight
challeng
problem
complex
biolog
long
timelin
low
probabl
success
also
stress
mani
differ
biotech
compani
big
pharma
includ
scope
resourc
sourc
innov
depend
success
individu
program
decis
make
risk
threshold
profit
made
accord
mike
key
success
includ
address
unmet
medic
need
real
market
leverag
innov
address
challeng
build
strong
leadership
team
e
echo
point
rais
bob
buckheit
mike
sofia
walk
audienc
compani
found
includ
transcel
technolog
pharmasett
oncor
latter
merg
tekmira
creat
arbutu
present
two
success
ceo
follow
lectur
intellectu
properti
ip
step
start
biotech
compani
rebecca
kaufman
king
spauld
llp
atlanta
ga
walk
audienc
variou
aspect
intellectu
properti
includ
patent
actual
requir
grant
patent
patent
coverag
pursu
stress
import
invent
disclosur
outset
patent
process
final
talk
isaac
r
rodriguezchavez
review
step
start
fund
biotech
compani
point
larg
pharma
downsiz
recent
year
annual
number
startup
grown
success
rate
success
stori
abound
isaac
also
highlight
reason
failur
includ
understand
valu
product
run
busi
circl
back
messag
first
two
speaker
emphas
success
startup
begin
solid
busi
plan
expert
provid
confer
attende
excel
overview
requir
risk
startup
process
elus
rhinoviru
c
histor
context
biolog
enigma
ann
palmenberg
univers
wisconsin
madison
ann
palmenberg
lectur
focus
fastdevelop
stori
rhinoviru
c
rvc
speci
wherea
type
b
known
mani
year
rhinovirusc
rvc
discov
part
sar
surveil
effort
rna
sequenc
reveal
new
type
rhinoviru
remain
hidden
rvc
replic
standard
rhinoviru
cell
cultur
assay
e
use
anoth
cellular
receptor
cadherinrel
protein
structur
topographi
rvc
differ
rva
rvb
rvc
spike
two
form
human
popul
report
import
suscept
factor
asthma
exacerb
one
frequent
caus
hospit
childhood
bonnelykk
et
al
highli
express
airway
epithelium
children
homozyg
higher
risk
asthma
exacerb
hospit
homozyg
ancestr
protein
found
mani
mammal
nonhuman
primat
neanderth
thought
diverg
modern
human
lineag
year
ago
dna
sequenc
show
retain
ancestr
protein
although
otzi
iceman
found
alp
protein
allel
discov
earli
human
specimen
indic
variant
spread
human
popul
africa
event
around
year
ago
current
major
human
group
allel
encod
protein
rang
africa
asia
could
rvc
evolv
exert
select
pressur
human
evolut
answer
question
phylogenet
tree
creat
mani
unpassag
clinic
isol
rhinovirus
type
b
c
preliminari
analysi
suggest
emerg
rvc
rva
year
ago
emerg
rvc
may
explain
protein
becom
domin
modern
human
popul
account
earli
appear
variant
ancient
human
dna
prior
africa
migrat
antivir
interfac
public
health
case
studi
polio
mark
pallansch
center
diseas
control
prevent
cdc
atlanta
ga
global
laboratori
network
support
worldwid
polio
erad
initi
gpei
start
partner
world
health
organ
rotari
cdc
unicef
aim
erad
polio
start
baselin
case
polio
per
year
countri
burden
diseas
markedli
reduc
sinc
hand
case
year
oral
vaccin
effect
reduc
number
new
case
small
reservoir
viru
identifi
immunocompromis
subject
prolong
replic
attenu
mutat
neg
select
pressur
vaccineassoci
paralyt
polio
case
per
vaccin
compar
per
wildtyp
viru
infect
variou
type
immun
defici
lead
prolong
viru
shed
month
sever
combin
immunodefici
scid
result
chronic
shed
year
vaccinederiv
polio
viru
immunodefici
subject
given
label
ivdpv
sinc
registri
record
known
ivdpv
case
initi
mainli
wellresourc
countri
increasingli
worldwid
encouragingli
ivdpv
shedder
identifi
greater
rate
due
improv
surveil
ivdpv
preval
studi
subject
enrol
chronic
shed
present
hazard
individu
diseas
may
progress
paralysi
death
commun
seed
new
polio
outbreak
therefor
potenti
role
antivir
therapi
assess
two
compound
pocapavir
capsid
inhibitor
proteas
inhibitor
identifi
potenti
progress
quickli
expect
two
drug
combin
caus
mark
reduct
viral
resist
frequenc
howev
remain
open
question
whether
combin
suffici
high
barrier
viral
resist
immunodefici
subject
diseas
progress
e
implic
treatment
cure
eric
hunter
emori
vaccin
center
atlanta
ga
hiv
transmiss
studi
serodiscord
coupl
one
hivposit
hivneg
allow
examin
donor
recipi
virus
recruit
coupl
studi
counsel
suppli
condom
reduc
expect
transmiss
rate
twothird
transmiss
occur
case
transmit
hiv
link
partner
viru
hiv
transmiss
involv
sever
genet
bottleneck
especi
male
partner
newli
infect
unless
male
genit
lesion
case
bottleneck
less
sever
compar
femal
partner
infect
hiv
transmiss
involv
select
chanc
quasispeci
present
transmit
partner
select
virion
closer
consensu
greater
transmiss
fit
consequ
select
follow
newli
infect
partner
year
year
asymptomat
setpoint
viral
load
vl
known
correl
diseas
progress
despit
select
hiv
transmiss
involv
select
chanc
individu
virion
differ
replic
capac
vrc
epitop
may
may
detect
new
host
immun
system
shown
earli
infect
highvrc
virus
link
enhanc
level
inflammatori
cytokin
drive
tcell
dysfunct
increas
viral
burden
cell
memori
cell
turn
link
significantli
faster
declin
cell
prior
immun
select
histori
render
transmit
viru
either
less
visibl
new
host
immun
system
hypothesi
transmiss
hiv
gag
polymorph
preadapt
recipi
hla
allel
could
reduc
immun
recognit
transmit
founder
viru
onaco
et
al
chanc
proport
founder
viru
may
alreadi
adapt
escap
immun
system
hand
virion
retain
consensu
epitop
easili
recogn
immun
system
evid
support
hypothesi
present
conclus
transmit
polymorph
impact
hiv
diseas
progress
low
vrc
origin
nonadapt
epitop
diseas
progress
slowli
high
vrc
adapt
epitop
aid
rapid
diseas
progress
altern
function
oppos
balanc
defin
virul
inactiv
subunit
vaccin
gener
better
safeti
profil
live
attenu
vaccin
may
provid
lifelong
immun
singl
dose
peiyong
investig
two
possibl
approach
develop
live
attenu
vaccin
zikv
knock
viral
methyltransferas
activ
site
thu
prevent
viru
acquir
cap
protect
viral
rna
delet
section
untransl
region
utr
latter
focu
icar
present
perhap
surprisingli
viru
delet
zikv
seem
promis
vaccin
candid
delet
mous
model
use
initi
evalu
safeti
efficaci
confirm
rhesu
macaqu
zikv
vaccin
well
toler
singl
dose
gave
protect
immun
within
day
postvaccin
mice
nonhuman
primat
vaccin
prevent
utero
transmiss
zikv
pregnant
mice
prevent
testi
damag
male
mice
possibl
answer
two
major
concern
clinic
studi
target
hiv
reservoir
stimul
elimin
jeff
murri
gilead
scienc
foster
citi
ca
jeff
murri
review
potenti
therapeut
approach
cure
hiv
infect
role
viru
latenc
antivir
drug
resist
major
barrier
cure
defin
three
type
cure
drugfre
remiss
function
cure
steril
cure
infect
cell
serv
reservoir
viral
persist
sourc
clonal
expans
latent
infect
cell
one
strategi
elimin
latent
infect
cell
shock
kill
treatment
regimen
use
latencyrevers
agent
tolllik
receptor
tlr
agonist
immun
activ
stimul
tlragonist
stimul
hiv
express
surprisingli
vaccin
increas
plasma
viremia
hivinfect
individu
activ
cell
increas
viru
express
jeff
describ
research
use
agonist
pattern
recognit
receptor
prr
ssrna
activ
cell
cell
use
therapeut
combin
antihiv
monoclon
antibodi
produc
synergist
effect
lead
increas
kill
infect
cell
also
describ
use
combin
therapi
agonist
therapeut
vaccin
intent
combin
latencyrevers
agent
immun
activ
catch
e
use
hbv
immun
therapi
ulrik
protzer
technic
univers
munich
germani
ulrik
protzer
describ
studi
immun
respons
hbv
infect
possibl
strategi
stimul
immun
therapi
state
tcell
respons
cure
hbv
infect
anim
model
interest
observ
acut
infect
patient
increas
cell
respons
contrast
chronic
infect
patient
decreas
respons
research
effort
focu
understand
interact
hbv
host
translat
knowledg
novel
therapeut
approach
lab
also
establish
two
hbvtransgen
mous
line
model
vertic
transmiss
develop
mous
model
selflimit
hbv
infect
ulrik
describ
sever
approach
therapi
includ
antivir
effect
cytokin
immun
mediat
antigen
target
therapeut
vaccin
adopt
transfer
antibodi
cell
reconstitut
hbvspecif
immun
therapeut
immun
respons
requir
low
hbv
load
reactiv
cell
recruit
liver
discuss
sever
recruit
strategi
includ
intrahepat
myeloidcel
aggreg
tcell
popul
expans
imat
chimericantigen
receptor
car
cell
recogn
hbv
antigen
mhcii
context
bispecif
antibodi
chimer
mous
model
possibl
except
car
tcell
effect
viral
load
first
lower
intern
unit
cytotox
cell
clear
cccdna
cultur
without
direct
contact
infect
cell
elimin
cccdna
ideal
tcell
target
must
dual
activ
includ
cytolyt
noncytolyt
effect
apobec
involv
cccdna
degrad
upregul
hbvinfect
human
liver
cell
dnase
also
requir
conclus
ulrik
suggest
immun
toler
must
overcom
cure
chronic
infect
lab
evalu
strategi
therapeut
vaccin
redirect
cell
hbvinfect
cell
gener
recombin
tcell
receptor
adolfo
garciasastr
mount
sinai
school
medicin
new
york
citi
ny
adolfo
garciasastr
describ
three
approach
identifi
host
factor
may
serv
influenza
viru
inhibitor
first
involv
use
sirna
screen
assay
identifi
confirm
host
factor
requir
influenza
viru
rna
replic
sever
identifi
inhibitor
transcript
activ
second
approach
base
highthroughput
screen
ht
assay
luciferas
gene
replac
hemagglutinin
ha
identifi
host
factor
potenti
antivir
target
ht
assay
requir
grow
recombin
virus
haexpress
cell
phenotyp
complement
result
singl
growth
cycl
noncompl
cell
assay
inhibitor
select
viru
resist
indic
potenti
host
factor
target
third
approach
involv
identif
target
influenza
viru
mrna
splice
export
adolfo
lab
identifi
cellular
bind
protein
mediat
viral
mprotein
mrna
splice
also
describ
novel
agonist
riboxxol
produc
immun
respons
intermedi
phenotyp
agonist
poli
c
basic
scienc
promis
antivir
hemorrhag
fever
virus
christina
spiropoul
cdc
atlanta
ga
lectur
christina
spiropoul
gave
overview
team
effort
develop
new
treatment
acut
sever
viral
diseas
focus
three
main
area
first
show
basic
understand
viral
biolog
pathogenesi
lead
novel
therapi
use
exampl
hantaviru
pulmonari
syndrom
develop
increas
vascular
permeabl
hantaviru
infect
lead
hypotens
shock
model
vitro
infect
cultur
endotheli
cell
group
demonstr
tyrosin
kinas
inhibitor
reduc
prevent
develop
vascular
leak
infect
primari
human
microvascular
endotheli
cell
rodent
model
suggest
would
benefit
human
patient
bird
et
al
second
part
lectur
christina
review
contribut
branch
discoveri
experiment
antivir
west
africa
ebola
epidem
discuss
shift
approach
drug
discoveri
outbreak
team
screen
rang
licens
therapeut
agent
goal
repurpos
treat
ebola
also
test
larg
number
potenti
new
antivir
particularli
success
effort
group
collabor
research
gilead
scienc
initi
character
eventu
demonstr
effect
novel
antivir
compound
ebola
viru
lo
et
al
sinc
gone
test
lethal
nipah
viru
infect
nonhuman
primat
collabor
emmi
de
wit
heinz
feldmann
nih
rocki
mountain
laboratori
close
talk
referenc
recent
develop
vspb
highthroughput
screen
assay
antivir
hemorrhag
fever
virus
agent
invit
futur
collabor
research
would
like
test
novel
compound
ultim
object
find
clinic
antivir
candid
david
safronetz
began
present
acknowledg
major
work
present
conduct
tenur
laboratori
virolog
rocki
mountain
laboratori
niaid
nih
hamilton
mt
session
focus
two
separ
rodentborn
viral
pathogen
uniqu
nuanc
associ
preclin
develop
test
medic
countermeasur
treat
prevent
infect
human
popul
first
topic
new
world
hantavirus
focus
primarili
and
sin
nombr
virus
caus
hantaviru
pulmonari
syndrom
hp
human
although
sever
studi
superb
protect
rate
prophylact
immun
studi
sporad
natur
human
infect
combin
rel
low
incid
rate
mani
geograph
region
suggest
therapeut
requir
treat
oppos
prevent
infect
high
risk
popul
therein
lie
problem
singl
small
anim
diseas
model
involv
infect
syrian
hamster
and
viru
preval
south
american
speci
hantaviru
model
recapitul
diseas
manifest
hp
accur
predict
valu
therapeut
studi
involv
immunomodulatori
compound
remain
unknown
clear
antivir
treatment
includ
ribavirin
favipiravir
well
therapeut
antibodi
treatment
prevent
lethal
diseas
human
current
treatment
onset
must
establish
prior
earli
viremia
onset
well
human
develop
clinic
ill
combin
therapi
need
explor
well
develop
anim
model
perhap
use
similar
strategi
recent
describ
nonhuman
primat
model
hp
order
advanc
treatment
option
made
rare
frequent
fatal
diseas
second
topic
lassa
viru
caus
lassa
fever
acut
hemorrhag
diseas
human
rel
well
defin
endem
region
across
west
africa
combin
predict
infect
rate
sever
hundr
thousand
individu
annual
suggest
immun
strategi
would
benefici
reduc
burden
diseas
howev
high
genet
divers
associ
lassa
viru
across
endem
region
rais
question
whether
univers
vaccin
achiev
region
variant
requir
mani
platform
evalu
though
homotyp
challeng
commonli
lassa
viru
strain
josiah
sierra
leon
use
vsvbase
lassa
vaccin
similar
recent
deploy
rvsvebov
vaccin
dave
group
seen
excel
result
challeng
model
clade
virus
howev
lack
character
model
use
lassa
clade
isol
slow
laboratori
investig
nevertheless
vsvlassa
vaccin
consid
frontlin
candid
use
west
africa
receiv
increas
attent
late
due
rvsvebola
trail
recent
west
african
outbreak
despit
recent
success
vaccin
experi
research
therapeut
treat
lassa
fever
also
prioriti
given
virus
repeat
introduct
outsid
west
africa
includ
europ
north
america
offlabel
use
ribavirin
current
consid
standard
care
human
dave
group
found
treatment
guinea
pig
nhp
favipiravir
demonstr
superior
protect
lethal
diseas
case
guinea
pig
model
revers
sign
advanc
diseas
even
treatment
initi
day
postinfect
typic
within
hour
given
favipiravir
alreadi
licens
treat
influenza
infect
human
countri
result
support
trial
treat
lassa
fever
human
mariano
garciablanco
colleagu
conduct
genomescal
rnai
screen
identifi
candid
host
factor
identifi
ribosom
protein
among
crucial
host
factor
requir
denv
yfv
infect
campo
et
al
phosphoprotein
bind
ribosom
interact
anoth
ribosom
protein
form
structur
term
ribosom
stalk
valid
essenti
host
factor
denv
yfv
zikv
infect
human
cell
line
knockdown
strongli
reduc
earli
denv
protein
accumul
indic
requir
viral
translat
addit
mariano
colleagu
interrog
librari
fdaapprov
drug
abil
block
infect
human
cell
newli
isol
zikv
strain
zikv
test
compound
decreas
zikv
infect
vitro
screen
assay
select
compound
valid
inhibit
zikv
infect
human
cervic
placent
neural
stem
cell
line
well
primari
human
amnion
cell
establish
antiflavivir
drug
eg
bortezomib
mycophenol
acid
other
previous
known
antivir
activ
eg
daptomycin
identifi
inhibitor
zikv
infect
studi
identifi
drug
could
test
clinic
studi
zikv
infect
provid
resourc
small
molecul
studi
zikv
pathogenesi
broadspectrum
antivir
prevent
emerg
coronaviru
pandem
diseas
timothi
sheahan
univers
north
carolina
chapel
hill
coronavirus
cov
procliv
spread
rapidli
new
host
speci
caus
new
diseas
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
cov
success
emerg
caus
sever
epidem
respiratori
diseas
immunolog
human
popul
throughout
globe
broadspectrum
therapi
capabl
inhibit
cov
infect
would
address
immedi
unmet
medic
need
could
invalu
treatment
emerg
cov
infect
timothi
sheahan
colleagu
show
nucleotid
prodrug
current
develop
treat
ebola
viru
diseas
inhibit
sarscov
merscov
replic
multipl
vitro
system
includ
primari
human
airway
epitheli
cell
cultur
submicromolar
ec
valu
ec
mm
good
select
index
si
human
murin
cell
line
also
effect
batcov
prepandem
batcov
circul
contemporari
human
cov
primari
human
lung
cell
thu
demonstr
broadspectrum
anticov
activ
mous
model
sarscov
pathogenesi
prophylact
earli
therapeut
administr
significantli
reduc
lung
viral
load
improv
clinic
sign
diseas
well
respiratori
function
adult
age
mice
sheahan
colleagu
demonstr
small
molecul
inhibitor
potent
vitro
vivo
antivir
efficaci
multipl
zoonot
epidem
contemporari
human
cov
data
provid
substant
evid
may
prove
effect
endem
merscov
middl
east
circul
human
cov
emerg
cov
futur
maria
agostini
vanderbilt
univers
nashvil
tn
present
data
antivir
activ
cov
analog
adenosin
cnucleosid
prodrug
also
show
broad
anticov
activ
less
potent
mutat
confer
resist
map
finger
domain
suggest
similar
mechan
action
overal
broadli
activ
divers
cov
effect
antivir
therapeut
known
emerg
cov
jinhong
chang
baruch
bloomberg
institut
doylestown
pa
present
data
antivir
activ
benzodiazepin
compound
bdaa
yellow
fever
viru
yfv
bdaa
resist
mutat
map
yfv
protein
bdaa
specif
enhanc
host
cellular
cytokin
respons
induc
yfv
virus
timeofaddit
experi
support
propos
mechan
action
bdaa
disrupt
integr
membraneassoci
yfv
rna
replic
complex
suppress
viral
replic
also
increas
exposur
viral
rna
enhanc
innat
cytokin
respons
linlin
zhang
institut
biochemistri
univers
germani
investig
antivir
activ
zikv
proteas
inhibitor
design
crystal
structur
zikv
complex
capsid
dipeptid
boron
inhibitor
zikv
proteas
fold
activ
compar
proteas
relat
flavivirus
wnv
develop
anim
model
emerg
virus
critic
antivir
develop
two
talk
institut
antivir
research
iar
utah
state
univers
discuss
anim
model
develop
emerg
virus
justin
juland
iar
present
data
test
live
attenu
zikv
vaccin
candid
develop
codagenix
inc
use
codon
deoptim
approach
two
vaccin
candid
test
lethal
zika
viru
mous
model
reverseengin
synthet
attenu
vaccin
candid
show
dosedepend
protect
correl
neutral
antibodi
level
present
serum
prior
viru
challeng
bart
tarbet
iar
discuss
develop
respiratori
neurolog
diseas
model
enteroviru
infect
mice
intranas
challeng
viru
rapidli
spread
lung
blood
tissu
includ
central
nervou
system
respiratori
diseas
sign
includ
histolog
lesion
increas
proinflammatori
cytokin
decreas
lung
function
measur
plethysmographi
intraperiton
challeng
paralysi
hind
limb
observ
prior
mortal
respiratori
neurolog
sign
could
prevent
administr
guanidin
kara
carter
sanofi
cambridg
discuss
develop
recombin
human
monoclon
antibodi
target
chikungunya
viru
chikv
two
independ
murin
model
chikv
diseas
recombin
antibodi
produc
dosedepend
reduct
viral
titer
joint
well
nonhuman
primat
model
diseas
candid
continu
develop
clinic
therapeut
evalu
well
prophylact
activ
assess
preclin
model
joana
rochapereira
rega
institut
medic
research
leuven
report
therapeut
activ
cmethyladenosin
cmethyl
cytidin
noroviru
rotaviru
infect
vitro
mous
model
namjoon
cho
nanyang
technolog
institut
singapor
discuss
approach
use
peptid
select
destabil
lipid
membran
potenti
antivir
therapeut
peptid
activ
multipl
viru
famili
therapeut
index
experi
model
dengu
human
mice
demonstr
reduc
viral
titer
treatment
victor
de
filippi
oregon
health
scienc
univers
portland
discuss
effect
interferon
ifn
activ
small
molecul
avc
target
viral
infect
zika
dengu
chikungunya
avc
requir
trifdepend
signal
cascad
culmin
depend
express
secret
ifni
elicit
antivir
respons
addit
human
peripher
blood
mononuclear
cell
treat
avc
secret
proinflammatori
cytokin
link
establish
adapt
immun
respons
juli
dyall
nih
integr
research
facil
frederick
md
discuss
antivir
activ
apilimod
pikfyv
inhibitor
ebov
marburg
virus
apilimod
inhibit
ebov
marburg
viru
infect
vero
primari
human
macrophag
cell
ec
nm
mechanist
studi
show
apilimod
block
ebov
entri
block
particl
deliveri
endolysosom
contain
niemannpick
intracellular
receptor
ebov
yasuteru
sakuari
texa
biomed
research
institut
san
antonio
discuss
discoveri
multipl
deriv
antimalari
amodiaquin
antiebov
activ
vitro
screen
reveal
compound
potent
activ
high
select
index
leen
delang
rega
institut
leuven
discuss
role
mosquito
vector
spread
drugresist
virus
colleagu
approach
question
look
replic
transmiss
abil
wildtyp
chikv
resist
chikv
variant
ie
madtp
resist
chikv
mutat
gene
favipiravir
resist
chikv
mutat
rdrp
gene
found
dissemin
favipiravirresist
chikv
within
mosquito
spread
viru
saliva
markedli
decreas
compar
wildtyp
madtpresist
virus
nevertheless
virus
retain
drugresist
phenotyp
mosquito
icar
present
summar
great
progress
hepat
c
therapi
last
year
highlight
remain
challeng
present
number
approach
move
success
anoth
hepatitiscaus
viru
hbv
differ
replic
cycl
hcv
hbv
relev
antivir
therapi
highlight
hcv
rna
viru
replic
exclus
cytoplasm
without
dna
intermedi
mean
establish
persist
latent
infect
wherea
hbv
replic
cycl
includ
closedcircular
cdna
cccdna
nuclearpersist
form
former
therefor
cure
drug
effici
inhibit
genom
replic
infect
new
cell
wherea
latter
also
requir
elimin
cccdna
reservoir
nonetheless
present
gener
optimist
lesson
learn
hcv
hiv
togeth
advanc
antivir
therapi
immunolog
eventu
lead
definit
hbv
cure
number
present
clearli
reflect
consensu
describ
mike
sofia
review
histori
develop
effect
direct
act
antivir
li
de
clercq
hcv
therapi
continu
new
hbv
capsid
inhibitor
ulrik
protzer
discuss
induct
cur
immun
chronic
hbv
lower
viral
load
target
immun
cell
ensu
talk
common
theme
emerg
approach
use
antivir
reduc
viral
load
combin
vaccin
immunemodul
elimin
cccdna
reservoir
like
succeed
cure
hbv
also
consensu
combin
therapi
essenti
hepat
b
hiv
hcv
infect
present
hepat
viru
session
describ
potenti
novel
antivir
wherea
sever
poster
focus
select
approach
induc
stronger
hbv
immun
john
tavi
saint
loui
univers
saint
loui
mo
propos
rnaseh
domain
hbv
polymeras
target
antivir
use
combin
therapi
rnaseh
difficult
enzym
work
vitro
system
perform
larg
scale
screen
firstgener
assay
undersensit
result
underestim
number
inhibitor
john
group
focus
known
hiv
rnaseh
inhibitor
start
compound
eventu
identifi
inhibitor
rnaseh
hbv
isol
genotyp
b
c
clone
activ
vari
approxim
sensit
two
inhibitor
inhibit
addit
experiment
capsid
inhibitor
synergist
lamivudin
two
compound
inhibit
viremia
fah
frg
chimer
mice
log
although
limit
toxic
select
resist
observ
far
poster
group
describ
rnaseh
inhibitor
deriv
nhydroxyisoquinolinedion
relat
polyoxygen
heterocycl
ec
submicromolar
micromolar
rang
cytotox
concentr
cc
midto
highmicromolar
rang
expect
inhibitor
block
synthesi
strand
dna
result
accumul
rna
dna
heteroduplex
vitro
cell
present
highlight
potenti
rnaseh
inhibitor
hbv
therapi
also
note
challeng
identifi
develop
compound
vitro
assay
still
intrins
limit
talk
shuo
wu
blumberg
institut
poster
present
masaaki
toyama
kagoshima
univers
japan
discuss
two
group
capsid
inhibitor
benzamid
pyrimidotriazinon
deriv
identifi
cellbas
silico
screen
approxim
compound
structur
respect
benzamidederiv
compound
identifi
wu
group
model
bind
hydrophob
pocket
capsid
shown
target
capsid
inhibitor
mutat
pocket
disrupt
antivir
activ
inhibitor
insensit
capsid
phosphoryl
induc
format
empti
capsid
inhibit
assembl
mix
drugsensit
drugresist
capsid
molecul
poster
present
andrea
cuconati
arbutu
biopharma
describ
combinatori
effect
capsid
inhibitor
lipidformul
sirna
nanoparticl
pegyl
interferon
nucleosidetid
analog
entecavir
tdf
taf
twoway
combin
evalu
stablytransfect
hbv
replic
cell
line
hbvinfect
primari
human
hepatocyt
combin
test
viral
dna
secret
hbv
protein
synergist
addit
antagonist
effect
detect
taken
togeth
present
support
develop
capsid
assembl
inhibitor
cellular
protein
also
examin
potenti
target
hbv
therapi
present
david
durantel
inserm
lyon
franc
discuss
inhibitor
pololik
kinas
enzym
activ
woodchuck
hepat
viru
carcinogenesi
hepatocellular
carcinoma
hbv
x
antigen
involv
cellcycl
regul
dna
repair
phosphorylationdephosphoryl
cycl
capsid
requir
hbv
encapsid
induc
hbv
even
nondivid
primari
human
hepatocyt
sirna
small
molecul
inhibitor
show
particip
hbv
replic
capsid
assembl
inhibit
inhibit
phosphoryl
capsid
prime
phosphoryl
srpk
plk
inhibitor
lower
viremia
frg
mice
log
mgkg
daili
without
effect
sag
express
obviou
toxic
effect
plk
inhibitor
propos
compon
combinatori
therapi
two
talk
focus
modul
antivir
cellular
respons
present
emili
thi
arbutu
biopharma
discuss
effect
sting
agonist
hbv
infect
model
sting
activ
result
reactiv
immun
respons
thu
break
immunotoler
support
model
previous
found
activ
sting
macrophag
result
inhibit
hcv
cultur
hepatoma
cell
like
sever
virus
hbv
inhibit
sting
two
sting
agonist
dmxaa
chemicallymodifi
cgamp
physiolog
sting
agonist
decreas
viremia
liver
hbv
load
adenoviru
mous
model
treatment
dmxaa
daili
day
caus
rapid
reduct
repeat
treatment
equal
surpass
inhibit
ifn
treatment
although
inhibit
highli
variabl
dmxaa
chemic
modifi
cgamp
structur
differ
unlik
antivir
effect
result
offtarget
effect
halfliv
molecul
vastli
differ
may
import
sting
activ
effect
sting
modul
tcell
prolifer
dendrit
cell
evalu
anoth
present
david
durantel
focus
ifn
tlr
agonist
immunomodul
reactiv
respons
hbv
agonist
shown
good
activ
woodchuck
chimpanze
activ
human
low
dose
could
use
moreov
express
hepatocyt
agonist
therefor
act
indirectli
contrast
express
hepatocyt
sever
tlr
agonist
test
hbv
infect
hepatocyt
day
infect
cccdna
reduc
wherea
viral
antigen
fulli
inhibit
indic
silenc
mechan
partli
involv
polyic
best
antivir
effect
rebound
within
day
stop
treatment
pure
alreadi
discuss
adolfo
garciasastr
riboxxxol
test
vivo
equal
activ
riboxxxol
induc
express
gene
nfkb
ifn
pathway
treatment
infect
hepatocyt
riboxxxol
condit
medium
riboxxxoltr
pbmc
result
similar
antivir
effect
indic
agonist
act
directli
infect
hepatocyt
indirectli
activ
immun
cell
antivir
activ
agonist
neutral
ifn
unfortun
agonist
challeng
formul
icar
highlight
great
success
hepat
c
therapi
renew
interest
hbv
target
antivir
intervent
ultim
goal
function
cure
gener
consensu
combin
therapi
immunomodul
necessari
achiev
goal
new
viral
cellular
target
explor
includ
cellular
protein
kinas
viral
rnaseh
capsid
stephan
ludwig
institut
virolog
alisch
wilhelmsunivers
germani
report
repurpos
kinas
inhibitor
influenza
viru
strategi
target
cellular
factor
essenti
viru
replic
aim
broad
antivir
activ
spectrum
prevent
resist
raf
mekerk
signal
cascad
requir
influenza
viru
iav
replic
trigger
nuclear
export
newli
assembl
viral
ribonucleoprotein
vrnp
inhibit
cascad
previous
shown
inhibit
viral
replic
first
licens
mek
inhibitor
treatment
malign
melanoma
ie
trametinib
mekinist
develop
pfizer
shown
effici
block
replic
differ
influenza
subtyp
vitro
vivo
compound
enhanc
mice
surviv
reduc
lung
viral
titer
even
treatment
start
h
infect
provid
prolong
treatment
window
compar
oseltamivir
haasbach
et
al
confoc
microscopi
studi
demonstr
mek
inhibitor
impair
nuclear
export
vrnp
trametinib
also
limit
hyperexpress
sever
cytokin
atriva
therapeut
current
develop
antivir
mekinhibitor
influenza
sharon
tamir
karyopharm
therapeut
newton
report
inhibit
anoth
cellular
target
nuclear
export
requir
export
import
iav
cargo
vrnp
verdinexor
inhibitor
nuclear
export
protein
exportin
broadspectrum
antivir
agent
efficaci
respiratori
syncyti
viru
rsv
hcv
hiv
venezuelan
equin
enceph
viru
veev
random
doubleblind
placebocontrol
doseescal
phase
clinic
trial
verdinexor
conduct
healthi
human
volunt
australia
evalu
safeti
toler
verdinexor
drug
gener
safe
well
toler
verdinexor
evalu
lethal
mous
model
iav
infect
balbc
mice
comparison
neuraminidas
inhibitor
oseltamivir
verdinexor
show
robust
antivir
activ
long
therapeut
window
initi
treatment
delay
day
postchalleng
reduct
lung
viral
titer
equival
seen
dose
begun
day
postinocul
verdinexor
also
prove
synergist
oseltamivir
jennif
picken
karyopharm
therapeut
report
also
modul
traffick
rsv
matrix
protein
critic
mediat
rsv
replic
viral
egress
viral
protein
traffick
within
nucleu
action
inhibit
rsv
replic
cell
cultur
therapeut
prophylact
result
mild
nuclear
accumul
rsv
protein
reduc
express
increas
express
without
induct
caspas
apoptot
pathway
modul
immun
factor
evidenc
chang
proinflammatori
cytokin
express
jia
meng
alio
biopharma
inc
south
san
francisco
ca
report
activ
human
metapneumoviru
hmpv
viru
first
identifi
netherland
second
lead
caus
pediatr
lower
respiratori
tract
infect
parent
molecul
lumicitabin
nucleosid
prodrug
inhibitor
rsv
replic
current
clinic
evalu
demonstr
potent
activ
variou
strain
hmpv
ec
valu
mm
rang
triphosph
form
recogn
substrat
rsv
hmpv
polymeras
caus
immedi
chain
termin
inhibit
polymeras
host
virus
unrel
rsv
hmpv
result
support
investig
treatment
hmpv
infect
pediatr
adult
patient
erik
rhoden
cdc
atlanta
describ
activ
antifung
azol
enteroviru
ev
parechoviru
caus
sever
ill
young
infant
includ
sepsi
mening
enceph
highlight
need
antivir
therapi
two
fdaapprov
antifung
azol
ie
itraconazol
itz
posaconazol
psz
well
inhibitor
enviroxim
oxysterolbind
protein
inhibitor
broadspectrum
antiev
ad
activ
consist
similar
mechan
action
ev
itz
psz
prove
activ
point
differ
mechan
action
itz
psz
target
earli
step
life
cycl
display
antivir
effect
pretreat
coaddit
cellfre
viruscompound
preincub
inactiv
attach
ketoconazol
fluconazol
voriconazol
antiev
activ
interestingli
itz
psz
specif
inhibitor
parechoviru
type
inhibit
studi
requir
identifi
potenti
receptor
involv
infect
herpesviru
dna
replic
reli
sever
process
typic
catalyz
enzym
nucleotidyltransferas
nt
superfamili
enzym
play
role
nucleic
acid
metabol
event
includ
rna
dna
digest
dna
recombin
dna
integr
replic
fork
repair
dna
repair
microrna
mirna
matur
function
viral
nt
enzym
includ
hbv
rnase
h
hiv
rnase
h
hiv
integras
sever
compound
select
abil
suppress
hiv
hbv
rnase
h
activ
previous
report
inhibit
hsv
replic
cell
cultur
lynda
morrison
saint
loui
univers
school
medicin
identifi
natur
tropolon
reduc
hsv
replic
log
mm
cell
cultur
also
report
antihsv
activ
synthet
tropolon
screen
first
colorimetr
assay
plaquereduct
assay
goal
determin
preliminari
structureact
relationship
sar
provid
start
point
futur
optim
studi
intact
ahydroxytropolon
aht
pharmacophor
advantag
antihsv
potenc
addit
aht
deriv
therefor
synthes
two
power
inhibitor
share
common
biphenyl
sidechain
capabl
inhibit
ec
nm
therapeut
index
also
strongli
inhibit
acyclovirresist
mutant
resist
nt
inhibitor
evolv
slowli
aht
deriv
present
higher
barrier
select
viral
resist
acyclovir
synergi
acyclovir
one
aht
deriv
report
troponoid
drug
envis
employ
alon
combin
exist
antihsv
drug
suppress
hsv
replic
order
prevent
viral
shed
limit
develop
drug
resist
select
herpesviru
drug
resist
wellrecogn
problem
among
divers
popul
patient
impair
immun
system
translat
research
platform
regavir
wwwregavirorg
set
belgium
type
drug
resist
among
patient
fail
antiherpesviru
therapi
graciela
andrei
rega
institut
leuven
present
sever
human
cytomegaloviru
hcmv
case
studi
highlight
use
rapid
genotyp
adjust
antivir
therapi
emerg
multipl
drugresist
due
either
infect
viru
singl
mutat
confer
resist
current
approv
drug
ganciclovir
cidofovir
foscavir
caus
coinfect
virus
distinct
genotyp
compartment
drugresist
hcmv
advantag
nextgener
sequenc
detect
minor
popul
drugresist
virus
emerg
resist
investig
antihcmv
drug
eg
maribavir
urgent
need
novel
antihcmv
agent
reduc
morbid
mortal
caus
drugresist
virus
therapi
congenit
infect
search
antiadenoviru
adv
agent
karoli
toth
saint
loui
univers
school
medicin
present
vitro
vivo
activ
alkyl
tyrosinamideest
prodrug
nucleotid
analog
hpmpa
consid
adenin
counterpart
cidofovir
prove
activ
multipl
adv
serotyp
cell
cultur
effect
hamster
immunosuppress
treatment
cyclophosphamid
oral
administr
complet
prevent
significantli
decreas
mortal
viral
titer
liver
patholog
administ
day
intraven
challeng
respiratori
challeng
model
patholog
chang
result
viral
replic
drug
administ
oral
mgml
bid
start
day
viru
inocul
diminish
viral
titer
lung
result
decreas
diseas
eventu
patholog
exacerb
drug
administr
evalu
loss
bodi
weight
indic
toxic
concentr
use
finetun
drug
concentr
intranas
challeng
model
plan
steven
de
jongh
rega
institut
leuven
propos
cyclin
gassoci
kinas
gak
target
hcv
therapi
gak
emerg
promis
drug
target
treatment
rna
viru
infect
gak
host
cell
kinas
deplet
sirna
shown
inhibit
two
distinct
step
hcv
replic
cycl
viral
entri
infecti
viru
assembl
hittolead
optim
process
isothiazolo
pyridin
led
develop
first
select
gak
inhibitor
also
activ
dengu
ebola
viru
favipiravir
metabol
biolog
activ
ribonucleosid
triphosph
extens
studi
potent
antivir
agent
howev
correspond
nucleosid
nucleotid
deriv
found
quit
unstabl
synthesi
problemat
johanna
hucht
hamburg
univers
germani
develop
reliabl
protocol
synthesi
monophosph
also
present
first
mechanist
studi
degrad
use
method
uvvi
nmr
spectroscopi
hplc
hresim
data
reveal
signific
labil
glycosid
bond
heterocycl
even
mild
condit
degrad
propos
begin
nucleophil
displac
fluorin
atom
hydroxyl
group
follow
destruct
heterocycl
moieti
glycosid
bond
cleavag
decomposit
nucleobas
incorpor
triphosph
viral
rna
also
lead
mutagen
effect
repres
one
possibl
mechan
action
favipiravir
nonnucleosid
revers
transcriptas
inhibitor
nnrti
repres
extens
studi
group
compound
treatment
infect
advantag
nnrti
compar
nucleosid
nucleotid
analog
requir
intracellular
metabol
ond
rej
baszczi
nski
institut
organ
chemistri
biochemistri
czech
academi
scienc
pragu
czech
republ
disclos
novel
type
nnrti
bear
core
quit
complic
lowyield
synthesi
afford
seri
compound
best
candid
exhibit
singledigit
nanomolar
activ
wildtyp
two
highli
preval
mutant
well
improv
solubl
compar
fdaapprov
nnrti
present
izzat
raheem
merck
west
point
ny
dealt
new
class
hiv
integras
strandtransf
inhibitor
insti
lead
compound
reveal
excel
antivir
activ
limit
oral
absorpt
uniqu
phosphatecarbon
acet
doubleprodrug
approach
therefor
develop
achiev
significantli
elev
plasma
exposur
lak
shin
jeong
seoul
nation
univers
south
korea
describ
design
synthesi
novel
fluorocarbocycl
nucleosid
sever
inhibit
zikv
chikv
submicromolar
rang
ec
mm
activ
compound
appear
correl
direct
inhibit
sadenosylhomocystein
hydrolas
viral
rna
polymeras
radim
nencka
institut
organ
chemistri
biochemistri
czech
academi
scienc
pragu
emphas
urgent
need
develop
potent
inhibitor
emerg
flavivirus
especi
easili
transmit
via
mosquito
tick
thu
call
arthropodborn
virus
arbovirus
team
recent
evalu
seri
nucleosid
nucleotid
analog
zikv
west
nile
viru
wnv
tickborn
enceph
viru
tbev
triphosph
deriv
select
nucleosid
prepar
evalu
inhibitori
activ
zikv
rnadepend
rna
polymeras
assay
team
success
establish
routin
compound
screen
promis
result
may
lead
design
novel
type
nucleosid
analog
hope
develop
potent
antivir
emerg
human
pathogen
